ABSTRACT
The COVID-19 pandemic caused an unprecedented disruption of food systems worldwide, with most governments taking severe containment measures to curb the spread. This resulted in unpredicted negative impacts of the agri-food supply chains coupled with food price inflations. Ultimately, this affected the food security and urban livelihoods for most households, who are dependent on urban markets for food supply. This study examined the implications of the pandemic on food prices and commodities supplies to urban markets conducted through structured interviews. A review of the secondary data was also conducted to show the trends of commodity prices over the last 5 years. The high inflation of commodity prices with a decline in sales volumes was reported by most traders (97%) with decreases in supply quantities. Changes in the consumption behaviour in households was reported by consumers (75%), with 65% experiencing reduced food diversity at home. Households adopted varied coping mechanisms, including reduced food portions (52%), reduced food varieties (44%) and skipping meals (32%). Market prices increased by an average margin of 13.8% for grains and pulses with price decline observed for cabbages (−30.8%) and Irish potatoes (−19.4%). The findings may inform policymakers of additional future shock and pandemic control protocols, whose actions would assure food protection of urban livelihoods. © 2023 by the authors.
ABSTRACT
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims. Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15 (th) July 2021 the database contains 12,419 projects, funded by 255 funders, taking place across 149 countries representing an investment of at least $4.9 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus. It is being used by the WHO, governments and multi-lateral policy makers, research funders and researchers. This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis will be presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio. Results: In this version five analysis we provide an updated detailed descriptive analysis of the database (three months after version four) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries). Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.
ABSTRACT
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims.
ABSTRACT
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
Subject(s)
Psoriasis/complications , Psoriasis/therapy , Humans , Psoriasis/psychologyABSTRACT
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There is however a need for greater coordination, with limited resources and the shifting global nature of the pandemic resulting in a proliferation of research projects underpowered and unable to achieve their aims.